Payment overview · 2025
General Payments
$13,891.10
228 reported records · 31 companies
Healthcare provider profile · identity verified
Fufu He, M.D
Allopathic & Osteopathic Physicians|Family Medicine · BROOKLYN, NY · NPI 1386601557
Verified facts
What the public records show
CMS Open Payments records show Fufu He, M.D received $13,891.10 in general payments during 2025 across 228 reported records.
Gilead Sciences, Inc. accounted for 37.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 54 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Arexvy, Creon, Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Nexletol, Prolia, Rybelsus, Shingrix, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 250 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nexium by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 416 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synjardy by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexletol by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 365 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 324 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 416 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 266 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $5,178.75 | 37.3% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $1,354.20 | 9.8% | 32 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $1,066.49 | 7.7% | 18 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $985.37 | 7.1% | 25 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $903.20 | 6.5% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $770.44 | 5.5% | 20 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $694.43 | 5.0% | 14 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $465.60 | 3.4% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $278.31 | 2.0% | 7 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $234.88 | 1.7% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $222.62 | 1.6% | 4 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $211.04 | 1.5% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $209.59 | 1.5% | 11 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $207.37 | 1.5% | 4 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $146.97 | 1.1% | 8 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $142.02 | 1.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $132.02 | 0.9% | 6 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $125.00 | 0.9% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $102.33 | 0.7% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $83.89 | 0.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $81.44 | 0.6% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $58.99 | 0.4% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $58.49 | 0.4% | 3 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.22 | 0.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.44 | 0.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.00 | 0.2% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $19.23 | 0.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.31 | 0.1% | 1 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $16.57 | 0.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.38 | 0.1% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $13.51 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $9,031.10 | 225 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,860.00 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $749.62 | 17 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $640.59 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $558.81 | 13 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $465.60 | 7 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $444.90 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $401.99 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $395.44 | 17 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $375.00 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $372.57 | 12 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $327.51 | 9 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $317.12 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $303.68 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $293.15 | 13 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $278.31 | 7 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $275.67 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $270.44 | 16 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $234.88 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $218.37 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $211.04 | 7 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $207.37 | 4 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $201.19 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $156.02 | 3 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $146.97 | 8 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $142.02 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $132.02 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $128.76 | 7 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Livdelzi Normalized: livdelzi |
Drug | Gilead Sciences, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $116.26 | 6 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $83.89 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $80.83 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $80.83 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $80.83 | 4 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $58.49 | 3 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $53.51 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $48.82 | 2 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $47.22 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $41.34 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $41.34 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| NEMLUVIO Normalized: nemluvio |
Drug | Galderma Laboratories, L.P. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $12.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 117 | exact normalized | Medicare Part D |
| AREXVY arexvy |
2025 | Arexvy | 2024 | 324 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 107 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 100 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 250 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 416 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 103 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 183 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 37 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 266 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 60 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 68 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
107 | 31 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
183 | 37 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
37 | 22 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
250 | 51 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
103 | 21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
416 | 90 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 22 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
365 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
324 | 323 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
60 | 45 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
416 | 90 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
266 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
117 | 117 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 22 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
43 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1518 | 388 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1303 | 338 |
| Diclofenac Epolamine | Diclofenac Epolamine | 1275 | 260 |
| Celecoxib | Celecoxib | 1143 | 333 |
| Losartan Potassium | Losartan Potassium | 1055 | 264 |
| Vascepa | Icosapent Ethyl | 924 | 189 |
| Alendronate Sodium | Alendronate Sodium | 836 | 202 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 820 | 209 |
| Tamsulosin Hcl | Tamsulosin Hcl | 719 | 171 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 706 | 220 |
| Meclizine Hcl | Meclizine Hcl | 673 | 269 |
| Omeprazole | Omeprazole | 615 | 216 |
| Montelukast Sodium | Montelukast Sodium | 607 | 210 |
| Fluocinonide | Fluocinonide | 600 | 301 |
| Metformin Hcl | Metformin Hcl | 518 | 118 |
| Gabapentin | Gabapentin | 424 | 101 |
| Jardiance | Empagliflozin | 416 | 90 |
| Diclofenac Sodium | Diclofenac Sodium | 388 | 171 |
| Vemlidy | Tenofovir Alafenamide | 365 | 39 |
| Bepotastine Besilate | Bepotastine Besilate | 360 | 136 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 324 | 323 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 323 | 78 |
| Zolpidem Tartrate | Zolpidem Tartrate | 312 | 94 |
| Simvastatin | Simvastatin | 310 | 71 |
| Dexlansoprazole Dr | Dexlansoprazole | 307 | 81 |
| Donepezil Hcl | Donepezil Hcl | 300 | 104 |
| Ammonium Lactate | Ammonium Lactate | 296 | 122 |
| Metoprolol Succinate | Metoprolol Succinate | 284 | 73 |
| Atenolol | Atenolol | 281 | 58 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 279 | 61 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 276 | 54 |
| Azithromycin | Azithromycin | 274 | 199 |
| Rybelsus | Semaglutide | 266 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 257 | 122 |
| Farxiga | Dapagliflozin Propanediol | 250 | 51 |
| Mupirocin | Mupirocin | 246 | 164 |
| Azelastine Hcl | Azelastine Hcl | 243 | 135 |
| Mometasone Furoate | Mometasone Furoate | 232 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 227 | 59 |
| Albuterol Sulfate | Albuterol Sulfate | 225 | 98 |
| Pioglitazone Hcl | Pioglitazone Hcl | 216 | 41 |
| Tizanidine Hcl | Tizanidine Hcl | 216 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 214 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 195 | 41 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 188 | 108 |
| Linzess | Linaclotide | 183 | 37 |
| Meloxicam | Meloxicam | 180 | 121 |
| Trazodone Hcl | Trazodone Hcl | 173 | 62 |
| Fenofibrate | Fenofibrate,micronized | 172 | 42 |
| Finasteride | Finasteride | 172 | 40 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 168 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 167 | 53 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 166 | 83 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 161 | 132 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 157 | 55 |
| Dicyclomine Hcl | Dicyclomine Hcl | 157 | 72 |
| Rivastigmine | Rivastigmine Tartrate | 157 | 33 |
| Allopurinol | Allopurinol | 149 | 61 |
| Famotidine | Famotidine | 147 | 39 |
| Metformin Hcl Er | Metformin Hcl | 138 | 33 |
| Dutasteride | Dutasteride | 134 | 34 |
| Rivastigmine | Rivastigmine | 129 | 21 |
| Januvia | Sitagliptin Phosphate | 126 | 21 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 123 | 23 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 117 | 117 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 117 | 54 |
| Furosemide | Furosemide | 116 | 36 |
| Raloxifene Hcl | Raloxifene Hcl | 114 | 27 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 113 | 21 |
| Colchicine | Colchicine | 112 | 43 |
| Creon | Lipase/Protease/Amylase | 107 | 31 |
| Kerendia | Finerenone | 103 | 21 |
| Eliquis | Apixaban | 100 | 22 |
| Halobetasol Propionate | Halobetasol Propionate | 99 | 46 |
| Gemfibrozil | Gemfibrozil | 98 | 26 |
| Cephalexin | Cephalexin | 96 | 85 |
| Restasis | Cyclosporine | 93 | 19 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 85 | 84 |
| Ezetimibe | Ezetimibe | 82 | 26 |
| Loperamide | Loperamide Hcl | 82 | 66 |
| Prednisone | Prednisone | 81 | 72 |
| Glipizide Er | Glipizide | 76 | 16 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 74 | 24 |
| Glimepiride | Glimepiride | 72 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 71 | 37 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 39 |
| Ibuprofen | Ibuprofen | 70 | 52 |
| Jentadueto | Linagliptin/Metformin Hcl | 69 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 13 |
| Sucralfate | Sucralfate | 66 | 27 |
| Hydrocortisone | Hydrocortisone | 65 | 33 |
| Procto-Med Hc | Hydrocortisone | 65 | 38 |
| Clonazepam | Clonazepam | 62 | 17 |
| Febuxostat | Febuxostat | 62 | 12 |
| Tradjenta | Linagliptin | 62 | 11 |
| Sertraline Hcl | Sertraline Hcl | 60 | 19 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 60 | 45 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 60 | suppressed |
| Carvedilol | Carvedilol | 59 | 15 |
| Naproxen | Naproxen | 59 | 37 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 57 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 33 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 51 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 15 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 51 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 50 | suppressed |
| Proctozone-Hc | Hydrocortisone | 50 | 16 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 48 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 46 | 30 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 44 | suppressed |
| Glipizide | Glipizide | 44 | suppressed |
| Nitroglycerin | Nitroglycerin | 44 | 23 |
| Trulance | Plecanatide | 43 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 42 | 30 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 41 | 23 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 39 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 38 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 37 | 16 |
| Lisinopril | Lisinopril | 37 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 37 | 11 |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Prolia | Denosumab | 37 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 34 | suppressed |
| Ketoconazole | Ketoconazole | 34 | 19 |
| Memantine Hcl Er | Memantine Hcl | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 33 | 20 |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Methimazole | Methimazole | 32 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 31 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 31 | 28 |
| Nateglinide | Nateglinide | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 29 | 16 |
| Clotrimazole | Clotrimazole | 29 | 11 |
| Lidocaine | Lidocaine | 29 | 15 |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Calcitriol | Calcitriol | 27 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 27 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 27 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 26 | 12 |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | 18 |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | 23 |
| Silver Sulfadiazine | Silver Sulfadiazine | 25 | 22 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | 23 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 24 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 19 |
| Propylthiouracil | Propylthiouracil | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Folic Acid | Folic Acid | 22 | 13 |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 20 | suppressed |
| Nexium | Esomeprazole Magnesium | 20 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 19 | suppressed |
| Cyclosporine | Cyclosporine | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | 13 |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Exelon | Rivastigmine | 16 | suppressed |
| Restasis Multidose | Cyclosporine | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | 12 |
| Single Use Swab | Alcohol Antiseptic Pads | 15 | 15 |
| Valsartan | Valsartan | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Edarbi | Azilsartan Medoxomil | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Multaq | Dronedarone Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Tobradex | Tobramycin/Dexamethasone | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | 11 |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 12 | suppressed |
| Desoximetasone | Desoximetasone | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Welchol | Colesevelam Hcl | 12 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Sodium Fluoride 5000 Plus | Fluoride (Sodium) | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13,891.10 · 228 records | Gilead Sciences, Inc. | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, Arikayce, Auvelity, BEYFORTUS, BREZTRI, Brinsupri, CAMZYOS, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, DUPIXENT, Dexcom G6 Transmitter, ELIQUIS, ENFLONSIA, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, Flector, GARDASIL 9, GEMTESA, IBSRELA, JARDIANCE, Kerendia, LINZESS, Licart, Livdelzi, NEMLUVIO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, PYRUKYND, REPATHA, REZDIFFRA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, Tirosint, VOWST, VYALEV, Veozah, Wegovy, XIFAXAN, ZENPEP, ZORYVE, ZTLido | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error